Peptide legality · Florida · updated 2026-09-21

Are peptides legal in Florida?

Gray area

In Florida, peptides sit in a legal gray zone: they are lawful only through a valid prescription filled by a licensed pharmacy, and they are not lawful when sold as research chemicals for self use.

Legal status overview

Florida places peptides in a gray zone that turns entirely on the prescription and licensed pharmacy pathway. The state has no peptide specific statute; the Florida Board of Pharmacy regulates compounding through Rule 64B16-27.700, which incorporates the federal 503A and 503B framework rather than adding peptide specific limits. Florida is widely viewed as a permissive market with a high concentration of wellness and telehealth clinics, yet a prescriber must still show a legitimate medical purpose and a proper patient evaluation, and products sold as research chemicals for human use have no lawful pathway. Brand name FDA approved medicines such as Wegovy® (semaglutide) remain fully legal by prescription, while many compounded peptides are in federal flux.

Key points

Florida has no statute or Board of Pharmacy rule that treats peptides as a distinct category; compounding follows Florida Administrative Code Rule 64B16-27.700, which relies on the federal 503A and 503B framework. ^[1]
A compounded peptide is lawful in Florida only when a licensed prescriber issues a valid prescription for a legitimate medical purpose and a licensed pharmacy or outsourcing facility prepares it; products marketed as research chemicals for self injection fall outside that pathway. ^[8]
Under Section 503A of the federal Food, Drug, and Cosmetic Act, a bulk drug substance may be compounded only if it has a USP or National Formulary monograph, is a component of an FDA approved drug, or appears on the 503A bulks list. ^[2]
BPC-157 and TB-500 are not FDA approved for human use and have no USP monograph; the FDA has reviewed them as bulk substances that may present safety risks, leaving compounded versions not FDA approved, not a generic, and not evaluated by the FDA. ^[3]
An FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23 to 24, 2026 considered whether BPC-157 should be added to the 503A bulks list, which means its compounding status remains unsettled at the federal level. ^[6]
The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, ending the shortage based exception that had allowed large scale compounding of copies of these GLP-1 medicines. ^[5]
Wind down deadlines applied nationwide, including Florida: 503A pharmacies had until April 22, 2025 and 503B facilities until May 22, 2025 to stop compounding semaglutide, with earlier February and March 2025 dates for tirzepatide. ^[4]
Federal law at 21 U.S.C. 333(e) restricts distribution of human growth hormone, defined as somatrem or somatropin, to recognized medical uses under a valid prescription, and the FDA reads writing a prescription for a non approved use as unlawful distribution. ^[7]

Compound-by-compound status

BPC-157 Gray area	Not FDA approved and no USP monograph; reviewed by the FDA as a bulk substance that may present safety risks and considered for the 503A bulks list at the July 23 to 24, 2026 advisory meeting. Any compounded BPC-157 is not FDA approved, not a generic, and not evaluated by the FDA, and is lawful in Florida only with a valid prescription filled by a licensed pharmacy.
GLP-1 class (Wegovy® (semaglutide), Ozempic® (semaglutide), Mounjaro® (tirzepatide), Zepbound® (tirzepatide)) Legal	These brand name medicines are FDA approved and fully legal in Florida by prescription. After the FDA resolved the tirzepatide and semaglutide shortages in late 2024 and early 2025, the shortage based exception ended, so compounded copies are now limited; compounded semaglutide or tirzepatide is not FDA approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta 4 fragment) Gray area	Not FDA approved and no USP monograph; reviewed by the FDA as a bulk substance that may present safety risks. Often sold as a research chemical, which has no lawful human use pathway in Florida; a compounded version would be not FDA approved, not a generic, and not evaluated by the FDA, and lawful only with a valid prescription and a licensed pharmacy.
Growth hormone peptides and somatropin (somatropin, sermorelin, CJC-1295, ipamorelin) Restricted	Somatropin (human growth hormone) is a prescription medicine whose distribution is restricted under 21 U.S.C. 333(e) to recognized medical uses. Sermorelin has a history of FDA approval and can be compounded with a prescription; CJC-1295 and ipamorelin are not FDA approved. In Florida these require a valid prescription for a legitimate medical purpose, and non approved use of growth hormone carries federal risk.

Frequently asked questions

Are peptides legal in Florida?

Peptides sit in a gray zone in Florida. They are lawful when a licensed prescriber writes a valid prescription for a legitimate medical purpose and a licensed pharmacy fills it. Products sold as research chemicals for self use have no lawful human use pathway. This is information, not medical or legal advice.

Can a Florida doctor prescribe compounded peptides such as BPC-157?

A Florida licensed prescriber may prescribe a compounded peptide when there is a legitimate medical purpose and a proper patient evaluation, and a licensed pharmacy prepares it under the federal 503A or 503B framework. Compounded BPC-157 is not FDA approved, not a generic, and not evaluated by the FDA.

Is compounded semaglutide or tirzepatide still available in Florida?

The FDA resolved the semaglutide and tirzepatide shortages in early 2025 and late 2024, which ended the shortage based exception that had allowed broad compounding. Brand name medicines such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) remain fully legal by prescription. Any compounded version is not FDA approved, not a generic, and not evaluated by the FDA.

Which agencies regulate peptides in Florida?

Oversight comes from the Florida Board of Pharmacy and its compounding rule, the Florida Board of Medicine and Florida Department of Health for prescriber conduct, and the FDA at the federal level for drug approval and compounding policy.

Is human growth hormone treated differently from other peptides?

Yes. Federal law at 21 U.S.C. 333(e) restricts distribution of human growth hormone, meaning somatrem or somatropin, to recognized medical uses under a valid prescription, and the FDA views a prescription for a non approved use as unlawful distribution, so growth hormone carries added legal risk beyond ordinary prescribing.

Sources

Fla. Admin. Code Ann. R. 64B16-27.700 (Compounding), Legal Information Institute (retrieved 2026-09-21)
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA (retrieved 2026-09-21)
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA (retrieved 2026-09-21)
FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide, NCPA (retrieved 2026-09-21)
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA (retrieved 2026-09-21)
July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee, FDA (retrieved 2026-09-21)
21 U.S.C. 333 (penalties, including subsection (e) on human growth hormone), Legal Information Institute (retrieved 2026-09-21)
Florida Peptide Laws and Regulations, PeptideLaws.com (retrieved 2026-09-21)

Last researched: 2026-09-21.

General information based on the sourced research above, not legal advice. For a specific situation in Florida, consult a licensed attorney familiar with pharmaceutical law.